D.E. Shaw & Co’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15,312
| Closed | -$155K | – | 4508 |
|
|
2024
Q4 | $155K | Sell |
15,312
-54,514
| -78% | -$659K | ﹤0.01% | 4122 |
|
|
2024
Q3 | $869K | Buy |
69,826
+13,552
| +24% | +$168K | ﹤0.01% | 3379 |
|
|
2024
Q2 | $732K | Sell |
56,274
-7,914
| -12% | -$131K | ﹤0.01% | 3381 |
|
|
2024
Q1 | $1.45M | Buy |
64,188
+23,040
| +56% | +$404K | ﹤0.01% | 2851 |
|
|
2023
Q4 | $534K | Sell |
41,148
-376
| -0.9% | -$5.07K | ﹤0.01% | 3483 |
|
|
2023
Q3 | $835K | Buy |
41,524
+1,673
| +4% | +$37.5K | ﹤0.01% | 3160 |
|
|
2023
Q2 | $1.07M | Buy |
39,851
+3,211
| +9% | +$138K | ﹤0.01% | 3043 |
|
|
2023
Q1 | $2.14M | Buy |
36,640
+16,109
| +78% | +$795K | ﹤0.01% | 2642 |
|
|
2022
Q4 | $1.05M | Buy |
20,531
+10,944
| +114% | +$759K | ﹤0.01% | 3413 |
|
|
2022
Q3 | $785K | Buy |
9,587
+5,687
| +146% | +$425K | ﹤0.01% | 3760 |
|
|
2022
Q2 | $264K | Buy |
3,900
+1,626
| +72% | +$149K | ﹤0.01% | 4414 |
|
|
2022
Q1 | $251K | Sell |
2,274
-9,463
| -81% | -$1.18M | ﹤0.01% | 4741 |
|
|
2021
Q4 | $1.13M | Buy |
+11,737
| New | +$1.17M | ﹤0.01% | 3824 |
|
|
2021
Q2 | – | Sell |
-991
| Closed | -$156K | – | 4885 |
|
|
2021
Q1 | $156K | Sell |
991
-91,151
| -99% | -$19.2M | ﹤0.01% | 3889 |
|
|
2020
Q4 | $21.4M | Sell |
92,142
-67,023
| -42% | -$15.5M | 0.02% | 928 |
|
|
2020
Q3 | $34.9M | Sell |
159,165
-39,169
| -20% | -$9.58M | 0.04% | 559 |
|
|
2020
Q2 | $56.3M | Buy |
198,334
+38,082
| +24% | +$11.3M | 0.07% | 330 |
|
|
2020
Q1 | $46.2M | Buy |
160,252
+2,551
| +2% | +$704K | 0.07% | 305 |
|
|
2019
Q4 | $45.3M | Buy |
157,701
+65,633
| +71% | +$14.2M | 0.05% | 437 |
|
|
2019
Q3 | $13.3M | Buy |
92,068
+38,371
| +71% | +$5.2M | 0.02% | 992 |
|
|
2019
Q2 | $4.82M | Buy |
53,697
+23,939
| +80% | +$1.92M | 0.01% | 1615 |
|
|
2019
Q1 | $2.61M | Buy |
29,758
+18,447
| +163% | +$2.04M | ﹤0.01% | 1976 |
|
|
2018
Q4 | $1.59M | Sell |
11,311
-3,573
| -24% | -$603K | ﹤0.01% | 2343 |
|
|
2018
Q3 | $3.8M | Buy |
14,884
+3,450
| +30% | +$954K | ﹤0.01% | 1752 |
|
|
2018
Q2 | $2.91M | Sell |
11,434
-269
| -2% | -$66.5K | ﹤0.01% | 1951 |
|
|
2018
Q1 | $2.36M | Buy |
11,703
+6,852
| +141% | +$1.37M | ﹤0.01% | 1938 |
|
|
2017
Q4 | $699K | Buy |
4,851
+814
| +20% | +$131K | ﹤0.01% | 2779 |
|
|
2017
Q3 | $665K | Sell |
4,037
-941
| -19% | -$135K | ﹤0.01% | 2749 |
|
|
2017
Q2 | $676K | Sell |
4,978
-4,740
| -49% | -$702K | ﹤0.01% | 2651 |
|
|
2017
Q1 | $1.87M | Buy |
9,718
+6,967
| +253% | +$1.12M | ﹤0.01% | 1885 |
|
|
2016
Q4 | $387K | Buy |
2,751
+870
| +46% | +$118K | ﹤0.01% | 2994 |
|
|
2016
Q3 | $275K | Buy |
+1,881
| New | +$226K | ﹤0.01% | 3083 |
|
|
2016
Q1 | – | Sell |
-3,180
| Closed | -$632K | – | 3611 |
|
|
2015
Q4 | $632K | Sell |
3,180
-67
| -2% | -$14.5K | ﹤0.01% | 2934 |
|
|
2015
Q3 | $513K | Buy |
+3,247
| New | +$868K | ﹤0.01% | 3046 |
|
Other funds holding KPTI
PAI
EP
CCM
APM
D.E. Shaw & Co's KPTI Position: Q1 2025 in Review
D.E. Shaw & Co sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 15,312 shares — an estimated $155K sold.
D.E. Shaw & Co first reported a position in KPTI in Q3 2015 and held it in 34 quarters. The position peaked at $56.3M in Q2 2020. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.
- D.E. Shaw & Co reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 15,312 Karyopharm Therapeutics shares in Q1 2025, an estimated $155K.
- D.E. Shaw & Co first reported a position in Karyopharm Therapeutics in Q3 2015 and held it in 34 quarters.
- D.E. Shaw & Co's Karyopharm Therapeutics position peaked at $56.3M in Q2 2020.
- 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.
Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.